These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 26390769)
21. Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction. Resnick RB Ann Intern Med; 2003 Feb; 138(4):360. PubMed ID: 12585846 [No Abstract] [Full Text] [Related]
22. Office-based practice and opioid-use disorders. Clark HW N Engl J Med; 2003 Sep; 349(10):928-30. PubMed ID: 12954740 [No Abstract] [Full Text] [Related]
23. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults. Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835 [TBL] [Abstract][Full Text] [Related]
24. The implementation of buprenorphine/naloxone in college health practice. DeMaria PA; Patkar AA J Am Coll Health; 2008; 56(4):391-3. PubMed ID: 18316282 [TBL] [Abstract][Full Text] [Related]
25. Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment. Barbosa-Leiker C; McPherson S; Layton ME; Burduli E; Roll JM; Ling W Am J Drug Alcohol Abuse; 2018; 44(4):488-496. PubMed ID: 29672167 [TBL] [Abstract][Full Text] [Related]
26. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Sullivan LE; Chawarski M; O'Connor PG; Schottenfeld RS; Fiellin DA Drug Alcohol Depend; 2005 Jul; 79(1):113-6. PubMed ID: 15943950 [TBL] [Abstract][Full Text] [Related]
27. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526 [TBL] [Abstract][Full Text] [Related]
28. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population. McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462 [TBL] [Abstract][Full Text] [Related]
29. Management of opioid painkiller dependence in primary care: ongoing recovery with buprenorphine/naloxone. Hard B BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25432908 [TBL] [Abstract][Full Text] [Related]
30. Drugs approved for opiate dependence. FDA Consum; 2003; 37(1):6. PubMed ID: 12625293 [No Abstract] [Full Text] [Related]